20 Best Biotech Stocks Under $20 to Buy Now

Page 10 of 18

9. Ardelyx, Inc. (NASDAQ:ARDX)

Number of Hedge Fund Holders: 30

Stock Price: $7.86

Ardelyx, Inc. (NASDAQ:ARDX) is next on our list.

TheFly reported on January 29 that TD Cowen raised its price target on ARDX to $13 from $10 while maintaining a Buy rating. The adjustment followed an update to the firm’s financial model ahead of the ARDX’s fourth-quarter results.

Additionally, on January 27, Jefferies also raised its price target on Ardelyx, Inc. (NASDAQ:ARDX) to $15 from $8 and maintained a Buy rating. The firm highlighted the company as one of the most underrated biotech launches and underlined sustained execution on Ibsrela in 2026, along with potential upside from IBS-C, new CIC indications, and extended intellectual property. Peak sales are now projected at $1.5–$2 billion by 2035, with additional upside if the new 2041 formulation patent proves defendable.

Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company focused on developing and commercializing first‑in‑class gastrointestinal and cardiorenal therapies. Its lead product, tenapanor, treats irritable bowel syndrome with constipation (IBS‑C) and chronic kidney disease‑related conditions.

Page 10 of 18